newsfilter
← Latest News
GlobeNewswire·

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million Expected to Support